Bayer sells off two older animal health drugs to Sanofi; Eli Lilly posts its first dividend increase since 2009;

@FiercePharma: Speaking of special reports, here's our newest: The top 10 patent expirations of 2015. Feature | Follow @FiercePharma

@EricPFierce: ICYMI: Third round of cuts slated for Novartis US Diovan plant. Total reaches 133 with 394 more gone by 2016. More | Follow @EricPFierce

@CarlyHFierce: Happy Hanukkah, #Pharma... here's a list of next year's biggest patent expirations. Article | Follow @CarlyHFierce

> Bayer is selling off two aging animal health products to Sanofi's ($SNY) animal health company, Merial. Story

> Eli Lilly ($LLY) posted its first dividend increase since 2009, boosting its quarterly dividend by 2%. More

> German regulators' ban on 80 generic drugs was halted due to appeals filed by manufacturers. Story

> France's Ipsen won FDA approval for its Somatuline Depot injection to treat gastroenteropancreatic neuroendocrine tumors. More

> Canadian drug manufacturer BioVectra is launching a $25 million overhaul of a former Sepracor plant. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Roche launches point-of-care, PCR molecular diagnostic system from $450M deal for iQuum. Report | Follow @FierceMedDev

@EmilyWFierce: Philips to acquire Volcano for $1.2B to expand in image-guided therapy. Report from Reuters | Follow @EmilyWFierce

> First pathogen reduction system for plasma approved by FDA. Article

> Smartphone plug-in launched for diagnosing ear infections. Item

Biotech News

@FierceBiotech: Amgen vet reveals stealth startup Flexus, backed by $38M from Kleiner Perkins, Celgene. News | Follow @FierceBiotech

@JohnCFierce: Auspex's Huntington's drug hits the mark in Phase III. Report | Follow @JohnCFierce

@DamianFierce: SV wealthbro Sean Parker pledges $24M to allergy research. Release | Still no word on his last effort. More | Follow @DamianFierce

> Playing a hot hand, Juno ups the ante on a $200M-plus IPO. News

> J&J rents Halozyme's R&D technology for up to $581M. Article

> Neovacs blasted after lead therapy flops in PhIIb for rheumatoid arthritis. Report

Drug Delivery News

> Study: Patients don't know how to use drug delivery devices. More

> Sanofi's newly approved intradermal quadrivalent Fluzone forgoes the shot. Item

> Molecular 'hats' disguise peptides until activated with UV light at a target. Article

> MIT spinoff Microchips finishes development of its birth control, osteoporosis implant. Story

> RNAi specialist Alnylam to focus on three therapeutic areas. Report

Diagnostics News

> Roche expands use of next-gen blood tests for organ and tissue screening. Report

> FDA approves diagnostic to spot blood cancer-causing virus. Story

> Ortho-Clinical Diagnostics launches Astute Medical's acute kidney injury test in U.S. hospitals. Item

> Ariosa Diagnostics nabs expanded national coverage for noninvasive prenatal test. Article

> Roche scoops up AvanSci Bio tissue dissection technology to bolster molecular Dx offerings. More

Pharma Marketing News

> Point-of-care marketing could shoot past DTC as pharma's latest trend. Report

> Marketing lesson from Actavis' Namenda ruling: For a hard switch, keep your mouths shut. More

> Actavis revs up new commercial team for post-Allergan-merger sales race. Story

> More CEO watchers put Gilead's Martin on their 'best of 2014' lists. Item

> Sanofi, Regeneron lay groundwork for PCSK9 rollout with Cholesterol Counts campaign. Article

And Finally… As deaths from painkiller overdoses increase in the U.S., some states are lobbying to make overdose-reversal drug naloxone more widely available to consumers. Story (sub. req.)

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.